Cancer Research and Treatment

Original Article

Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer: Young Saing Kim, Junshik Hong, Sun Jin Sym, Se Hoon Park, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Dong Bok Shin; Cancer Res Treat. 2010;42(1):24-29. Published online March 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.1.24

Purpose

This study was designed to determine the efficacy and safety of FOLFOX-4 chemotherapy as a salvage treatment for patients with advanced gastric cancer (AGC).

Materials and Methods

The AGC patients with an ECOG performance status of 0~1 and progressive disease after prior treatments were registered onto this phase II trial. The patients received oxaliplatin (85 mg/m² on day 1), leucovorin (200 mg/m² on days 1 and 2) and 5-fluorouracil (400 mg/m² as a bolus and 600 mg/m² as a 22-hour infusion on days 1 and 2) every 2 weeks.

Results

For the 42 treated patients, a total of 228 chemotherapy cycles (median: 5, range: 1~12) were administered. Twenty-nine patients (69%) received FOLFOX-4 chemotherapy as a third-(50%) or fourth-line (19%) treatment. On the intent-to-treat analysis, 9 patients (21%) achieved a partial response, which was maintained for 4.6 months. The median progression-free survival and overall survival were 3.0 months and 6.2 months, respectively. The frequently encountered toxicities were neutropenia and gastrointestinal side effects, including anorexia. Although there was one possible treatment-related death, the toxicity profiles were generally predictable and manageable.

Conclusion

Salvage chemotherapy with FOLFOX-4 is an effective and tolerable regimen for those heavily pretreated AGC patients who have a good performance status.

Citations

Citations to this article as recorded by

Strategic Developments in Polymer-Functionalized Liposomes for Targeted Colon Cancer Therapy: An Updated Review of Clinical Trial Data and Future Horizons
Satyam Sharma, Moitrai Chakraborty, Dharmendra Yadav, Aniket Dhullap, Raghuraj Singh, Rahul Kumar Verma, Sankha Bhattacharya, Sanjiv Singh
Biomacromolecules.2024; 25(9): 5650. CrossRef
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma
Domenico D’Arca, Leda Severi, Stefania Ferrari, Luca Dozza, Gaetano Marverti, Fulvio Magni, Clizia Chinello, Lisa Pagani, Lorenzo Tagliazucchi, Marco Villani, Gianluca d’Addese, Isabella Piga, Vincenza Conteduca, Lorena Rossi, Giorgia Gurioli, Ugo De Gior
Cancers.2023; 15(2): 412. CrossRef
Melatonin as an adjuvant treatment modality with doxorubicin [Biochimie 200 (2022) 1–7]
Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
Biochimie.2022; 200: 1. CrossRef
Melatonin as an adjuvant treatment modality with doxorubicin
Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
Biochimie.2022; 202: 49. CrossRef
A Phase I Study of Pevonedistat Plus Capecitabine Plus Oxaliplatin in Patients With Advanced Gastric Cancer Refractory to Platinum (NCCH-1811)
Hirokazu Shoji, Daisuke Takahari, Hiroki Hara, Kengo Nagashima, Jun Adachi, Narikazu Boku
Future Science OA.2021;[Epub] CrossRef
Design principles of drug combinations for chemotherapy
Debra Wu, Anusha Pusuluri, Douglas Vogus, Vinu Krishnan, C. Wyatt Shields, Jayoung Kim, Amaya Razmi, Samir Mitragotri
Journal of Controlled Release.2020; 323: 36. CrossRef
A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies
Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Chihiro Kondoh, Isao Oze, Kyoko Kato, Toshiki Masuishi, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Masashi Ando, Tsutomu Tanaka, Masahiro Tajika, Kei Muro
Advances in Therapy.2020; 37(6): 2853. CrossRef
The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study
Masoud Najafi, Keywan Mortezaee, Mahban Rahimifard, Bagher Farhood, Hamed Haghi-Aminjan
Life Sciences.2020; 257: 118051. CrossRef
Potential therapeutic effects of curcumin in gastric cancer
Nastaran Barati, Amir A. Momtazi‐Borojeni, Muhammed Majeed, Amirhossein Sahebkar
Journal of Cellular Physiology.2019; 234(3): 2317. CrossRef
Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee
Cancer Research and Treatment.2019; 51(1): 223. CrossRef
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan
Chihiro Kondoh, Shigenori Kadowaki, Azusa Komori, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Kei Muro
Gastric Cancer.2018; 21(6): 1050. CrossRef
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
In Sil Choi, Mihong Choi, Ju Hyun Lee, Jee Hyun Kim, Koung Jin Suh, Ji Yun Lee, Beodeul Kang, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
PLOS ONE.2018; 13(6): e0198544. CrossRef
A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
In Sil Choi, Jee Hyun Kim, Ju Hyun Lee, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
PLOS ONE.2018; 13(10): e0205853. CrossRef
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
Vincenza Conteduca, Giorgia Gurioli, Lorena Rossi, Emanuela Scarpi, Cristian Lolli, Giuseppe Schepisi, Alberto Farolfi, Delia De Lisi, Valentina Gallà, Salvatore Luca Burgio, Cecilia Menna, Andrea Amadori, Lorena Losi, Dino Amadori, Maria Paola Costi, Ugo
BMC Cancer.2018;[Epub] CrossRef
Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX
Sung Yong Oh, Aesun Shin, Seong-Geun Kim, Jung-Ah Hwang, Seung Hyun Hong, Yeon-Su Lee, Hyuk-Chan Kwon
Oncotarget.2016; 7(21): 31204. CrossRef
Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke, Jian-wei Bi
Tumor Biology.2014; 35(4): 2941. CrossRef
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
Suee Lee, Sung Yong Oh, Sung Hyun Kim, Ji Hyun Lee, Min Chan Kim, Ki Han Kim, Hyo-Jin Kim
BMC Cancer.2013;[Epub] CrossRef
The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Jung-Ah Hwang, Seung Hyun Hong, Christian A Graves, Kevin Camphausen, Hyo-Jin Kim, Yeon-Su Lee
BMC Cancer.2013;[Epub] CrossRef
Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy
Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Christian A. Graves, Kevin Camphausen, Hyo-Jin Kim
Chemotherapy.2012; 58(6): 426. CrossRef
Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study
K. Tsuji, H. Yasui, Y. Onozawa, N. Boku, H. Doyama, A. Fukutomi, K. Yamazaki, N. Machida, A. Todaka, H. Taniguchi, T. Tsushima, T. Yokota
Japanese Journal of Clinical Oncology.2012; 42(8): 686. CrossRef
The clinical research of elemene emulsion combined with FOLFOX4 regimen in the treatment of advanced gastric carcinoma
Yanzhi Bi, Dongxiang Zeng, Yang Ling
The Chinese-German Journal of Clinical Oncology.2012; 11(6): 336. CrossRef
Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor
Jun Chul Park, Jae-Hoon Lee, Kungseok Cheoi, Hyunsoo Chung, Mi Jin Yun, Hyuk Lee, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee
European Journal of Nuclear Medicine and Molecular Imaging.2012; 39(7): 1107. CrossRef
Comparison of the Toxicities and Efficacies of the Combination Chemotherapy Regimens in Advanced Gastric Cancer Patients Who Achieved Complete Response after Chemotherapy
Yun Jeung Kim, Pyung Gohn Goh, Eui Sik Kim, Su Youn Lee, Hee Seok Moon, Eaum Seok Lee, Jae Kyu Sung, Seok Hyun Kim, Byung Seok Lee, Hyun Yong Jeong
The Korean Journal of Gastroenterology.2011; 58(6): 311. CrossRef
Targeted Therapies for Gastric Cancer
Jaclyn Yoong, Michael Michael, Trevor Leong
Drugs.2011; 71(11): 1367. CrossRef
Evolving Standards of Care in Advanced Gastric Cancer
Jean-Emmanuel Kurtz, Patrick Dufour
Future Oncology.2011; 7(12): 1441. CrossRef

12,197 View
122 Download
25 Crossref

First
Prev
Page of 1
Next
Last

Search